Intended for healthcare professionals

CCBYNC Open access

Rapid response to:

Research

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

BMJ 2018; 360 doi: https://doi.org/10.1136/bmj.k119 (Published 06 February 2018) Cite this as: BMJ 2018;360:k119

Rapid Response:

Re: Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study

Cardiovascular benefit is encouraging but should not be assessed in isolation.

Could the authors please comment on the incidence of amputations in their cohort of patients (almost double control rate in a recent article in the NEJM, 29% of which above the ankle) ?

Competing interests: No competing interests

06 February 2018
Piero BAGLIONI
Consultant Physician
Prince Charles Hospital
Gournos Road, Merthyr Tydfill